Oryzon Genomics - Strengthening vafidemstat’s IP profile
Oryzon Genomics continues to fortify its IP profile for vafidemstat, which is being developed for borderline personality disorder (BPD) and for the...
151 Views
Oryzon Genomics - Encouraging interim update on FRIDA
Oryzon Genomics has reported positive interim data from the Phase Ib FRIDA study, evaluating iadademstat in combination with gilteritinib in...
184 Views
Oryzon Genomics - ALICE data published in The Lancet Haematology
Oryzon Genomics has announced the publication of the final ALICE trial results in the recognised peer-reviewed journal The Lancet Haematology. The...
216 Views
Oryzon Genomics - EC taps Oryzon for healthcare initiative
The European Commission has selected Oryzon to support a new healthcare initiative furthering innovation in the region. As an associated partner of...
237 Views
Oryzon Genomics - Doubling down on clinical activity in 2024
Oryzon’s Q124 results emphasised the company’s focus on advancing and expanding its CNS and oncology pipelines, driven by its core assets,...
213 Views